Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases
On November 23, 2021, Vipergen announced a multi-target drug discovery agreement with Aligos Therapeutics (Nasdaq: ALGS). This collaboration utilizes Vipergen's DNA-encoded library (DEL) technology to discover small-molecule compounds targeting specific proteins developed by Aligos for treating viral and liver diseases. Aligos will maintain exclusive rights for global commercialization of any resulting products. Financial details remain undisclosed, but Vipergen aims to enhance Aligos' drug portfolio, addressing critical health needs in chronic hepatitis B, NASH, and coronavirus.
- Establishment of a multi-target drug discovery agreement with Aligos Therapeutics.
- Utilization of advanced DEL technology, enhancing Aligos' drug development capabilities.
- Aligos retains exclusive rights for global commercialization, potentially boosting future revenues.
- No financial details disclosed, leaving uncertainty about the potential economic impact.
COPENHAGEN, Denmark, Nov. 23, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected Aligos protein targets. Aligos will select hits for development into novel therapeutics for viral and liver diseases. Aligos will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.
"We are delighted to collaborate with Aligos' highly experienced team in its mission to develop best-in-class therapies that improve treatment outcomes in chronic hepatitis B, NASH, and coronavirus," said Nils Hansen, PhD, Chief Executive Officer of Vipergen. "We look forward to applying our suite of DEL technologies to discover novel leads that help expand Aligos' portfolio of differentiated drug candidates that target these significant unmet medical needs."
About Vipergen ApS
Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.
Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com
View original content:SOURCE Vipergen
FAQ
What is the partnership between Vipergen and Aligos Therapeutics about?
When was the multi-target drug discovery agreement announced?
What technology does Vipergen use in its collaboration with Aligos?
What diseases are targeted through the Vipergen and Aligos partnership?
What are the commercialization rights for Aligos in the agreement?
